Mario Naranjo-Tovar (@MarioNaranjoMD) header
Mario Naranjo-Tovar (@MarioNaranjoMD) profile picture

Pulmonary & Critical Care Attending @TempleLung via @JHUPCCMFellows | MHS @JohnsHopkinsSPH | IM via @JeffHealthEH | PH & RV enthusiast #ThePeoplesVentricle

Philadelphia, PA
Joined April 2015
Photo by Mario Naranjo-Tovar (@MarioNaranjoMD)Photo by Mario Naranjo-Tovar (@MarioNaranjoMD)Photo by Mario Naranjo-Tovar (@MarioNaranjoMD)Photo by Mario Naranjo-Tovar (@MarioNaranjoMD)Photo by Mario Naranjo-Tovar (@MarioNaranjoMD)Photo by Mario Naranjo-Tovar (@MarioNaranjoMD)
Mario Naranjo-Tovar retweeted
Temple Lung Center continues to lead in lung care & transplantation. In 2024, we surpassed national benchmarks with a 90%+ survival rate in lung transplants and offer 50+ clinical trials for breakthrough therapies. Learn more: bit.ly/3YfBrTy
1
3
196
Mario Naranjo-Tovar retweeted
On #WorldLungDay we reflect on the global impact of chronic respiratory diseases, and unite to promote better lung health for all. We remain committed to expanding access to preventative services and treatment–and advancing lung health through research, advocacy & education.
1
3
436
Mario Naranjo-Tovar retweeted
Temple University Hospital once again leads the nation, performing more lung transplants than any other center in 2022. With the dedication of our transplant team, we're able to perform transplants for some of the most complex cases, with leading outcomes: bit.ly/45HWXlg
1
10
2
44
3,892
AVR was as high as 15% in prevalent non-IPAH patients! A less stringent AVR definition may prove to be a useful indicator for a subgroup of patients with more favorable outcomes in response to PAH therapy.
1
2
213
Do we need to reassess AVR? Is AVR response at follow‐up, with a possible survival advantage, related to long‐term PAH therapy affecting pulmonary vasomotor response and/or vascular remodeling? Exciting future ahead!!
1
171
Excited to join the amazing faculty, fellows, and staff at Temple University - Department of Thoracic Medicine & Surgery. Looking forward to working, collaborating, and learning from you all @TempleLung @TempleHealth @TemplePCCM
7
49
2,419
Excellent talk by @SteveMathaiMD addressing a very important topic “Current Outcome Measures in PH” @HopkinsPCCM @JHUPCCMFellows @ATS_PC @atscommunity
1
7
25
1,616
Mario Naranjo-Tovar retweeted
Is there anything better than a selfie with our best & brightest #NewFacultyBootcamp #ATS2023 #FutureIsBright Yes 👇🏼 – at Washington, DC
1
3
17
2,294
Today is #WorldPHDay2023! Now through May 31, join us in raising #pulmonaryhypertension awareness; advocating for access to #PH diagnosis, treatment and care; and celebrating the lives of people with PH. Learn how you can get involved. ow.ly/TiLo50NRUVe.
25
3
42
4,351
Mario Naranjo-Tovar retweeted
Today is #WorldPHDay 2023! We hope to raise awareness for #PulmonaryHypertension continue working on #research and in the clinic to improve the lives of our patients living with #PH! @PHAssociation @PVRI @3CPRCouncil @CHESTPulmCardio @ErsPvd @atscommunity
15
28
2,714
Mario Naranjo-Tovar retweeted
Pulmonary vascular disease is relevant to many practising respiratory clinicians: ∼1% of the world's population is estimated to have PH, and it is an important consequence of many other respiratory diseases (e.g. COPD, ILD, sleep breathing disorders) https://nitter.cf/t.co/y2hKmHhLvd
15
33
5,592
Transplant-free survival has improved significantly for Group 1 over the last decade, possibly secondary to earlier detection and better therapeutic management. This emphasizes the importance of robust screening and optimization of PAH therapy.
1
3
Conversely, those with Group 2 or 3 disease continue to have dismal prognosis and warrants further studies to explore better treatment and management strategies.
3